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Introduction {#sec1}
============

Chimeric antigen receptor (CAR)-engineered T cells have been approved for the treatment of CD19+ cell malignancies ([@bib27]). Unfortunately, it has been difficult to extend CAR T cell therapies beyond hematological malignancies to other types of cancer, specifically solid tumors ([@bib26]). To better engineer CAR T cells to fight cancer, we need to improve our understanding of how these modified receptors activate T cells.

CARs typically include an extracellular antibody-derived binding domain linked to a transmembrane domain and a number of different intracellular signaling domains ([@bib34]). These signaling domains are derived from endogenous T cells and typically include CD3ζ, a part of the endogenous T cell receptor (TCR), and a co-stimulatory domain, such as CD28. It is clear that T cells require this secondary signaling through a co-stimulatory receptor, but the mechanisms through which co-stimulatory domains influence T cell activation are not clear ([@bib7]). Additionally, although the strong early signaling events initiated by CARs and the endogenous T cell receptor (TCR) are similar ([@bib15]), it is clear that the more subtle signaling differences lead to vastly different functionalities between CAR- and TCR-stimulated T cells.

Computational mechanistic models can be used to test hypotheses about molecular signaling mechanisms. These models have been used in the past to study endogenous T cell activation, providing insights into important activation and feedback mechanisms that help control the sensitivity and specificity of TCR activation, reviewed previously ([@bib31]). These models generally assume that T cell activation is derived directly from the TCR CD3ζ signaling domain, while neglecting the effects of the co-stimulatory domains. Therefore, the immunology field has developed a fairly clear picture of the signaling events downstream of CD3ζ, but there is a lack of understanding of the effects of co-stimulation.

Recently, we have used phospho-proteomic mass spectrometry combined with mechanistic computational modeling to gain more insight into the effects of co-stimulation. We quantified the site-specific phosphorylation kinetics of CARs containing CD3ζ with or without CD28 (referred to as 28z and Z, respectively) ([@bib32]). Our experimental data showed that CD3ζ immunoreceptor tyrosine-based activation motifs (ITAMs) are phosphorylated independently, in a random order, and with distinct kinetics. Adding the CD28 co-stimulatory domain increased the rate of CD3ζ phosphorylation by over 3-fold. In addition, by applying the model, we identified that LCK phosphorylates CD3ζ through a mechanism of competitive inhibition. However, our previous experimental and modeling approach was limited; it did not include any signaling pathways and could not determine whether the increase in CD3ζ phosphorylation affects downstream signaling. More generally, it is not clear how any of the effects of CD28 influence downstream T cell activation. We are particularly interested in activation of the MAPK signaling pathway, leading to ERK phosphorylation. Although MAPK signaling is just one aspect of T cell activity, this pathway exhibits clear switch-like response in T cells and strongly contributes to T cell activation and proliferation ([@bib3]).

To explain how the CAR intracellular domains influence ERK response time, we constructed a mechanistic computational model of T cell activation by CARs containing the CD3ζ domain alone or in combination with CD28. We first calibrate the model using published experimental data and show that the model is able to reproduce known effects of various intracellular protein perturbations on ERK response time following T cell activation. We then investigated the model to explore the individual and combined effects of three possible mechanisms of CD28 co-stimulation, active CD28 recruitment of Grb2, GADS, or LCK, each based on previously published observations. Experimental measurements of ERK response in CAR-engineered T cells validate the model-generated hypothesis that CD28 activates ERK primarily through modifications of CD3ζ phosphorylation kinetics, likely as a result of increased recruitment of LCK. The model also generates additional hypotheses that can be used to guide new experiments. Specifically, the model predicts that removing ITAM sites from CD3ζ on the CAR can lead to faster activation with less negative feedback at high antigen concentrations. Overall, this modeling study enriches our understanding of CAR T cell co-stimulatory activation.

Results {#sec2}
=======

Model of CAR-mediated ERK Activation {#sec2.1}
------------------------------------

We constructed a computational mechanistic model that describes the early CAR signaling events leading to T cell activation. We specifically predict how the CAR mediates ERK activation through the MAPK pathway. Studies have indicated that, although the activation of CARs and TCRs have different signal initiating components, the signaling events initiated downstream are not significantly different ([@bib15]). Therefore, to construct our model, we combined four mechanistic signaling modules: (1) CAR-specific phosphorylation based on our previously published models, (2) phosphatase activity, (3) an LAT signalosome, and (4) an MAPK pathway that leads to ERK activation ([Figure 1](#fig1){ref-type="fig"}). To characterize the model, we first explored signaling primarily through the CD3ζ CAR stimulatory domain. This allowed us to compare our model with previously developed models in the literature, which largely simplify the TCR to account only for the CD3ζ domain.Figure 1Schematic of Signaling Model from CAR Antigen Binding Through ERK Activation, Incorporating Models from literatureArrows and bars indicate activating and inhibitory interactions, respectively. Dashed lines denote the same species in multiple Modules.Module I: LCK regulation, autophosphorylation, and phosphorylation of the CAR intracellular signaling domains and ZAP-70.Module II: CD45 and SHP1 phosphatase activity. CD45 is constitutively active in resting T cells, but it is excluded from the signaling area upon CAR binding to its ligand. SHP1 is recruited to the area by singly phosphorylated CD3ζ ITAMs and is activated by LCK.Module III: the LAT signalosome forms when ZAP-70 binds to doubly phosphorylated ITAMs and becomes phosphorylated by LCK. It can then phosphorylate sites on LAT and SLP76. Phosphorylated sites on LAT can bind proteins Grb2, GADS, and PLCγ. Grb2 can bind to SOS, whereas GADS binds to SLP76. SLP76 recruits Tec family kinases, such as ITK, which can then phosphorylate and activate PLCγ.Module IV: PLCγ and SOS can activate Ras-GDP to Ras-GTP. Ras-GTP can be inactivated by RasGAP. Once activated, RAS-GTP can activate the MAPK pathway, which leads to ERK activation. Doubly phosphorylated ERK can phosphorylate LCK at a protection site, which prevents LCK from associating with SHP1, resulting in a positive feedback loop.

Module I focuses on LCK autoregulation and its phosphorylation of the CAR intracellular signaling domains and ZAP-70. We first adapted our model of LCK autoregulation and inhibitory phosphorylation by the kinase CSK to reduce the computational complexity ([@bib30]). The second mechanistic element in this module was adapted from work from our lab to quantify the kinetics of CAR intracellular domain phosphorylation by LCK ([@bib32]). Our published computational quantification, paired with novel *in vitro* phospho-proteomic mass spectrometry, specifically identified the phosphorylation rates of individual tyrosine sites. This work also revealed that the addition of CD28 increases the rate of CD3ζ ITAM phosphorylation, which will be used later in the present study to explore how CD28 affects downstream signaling in the T cell activation system. Once CD3ζ ITAMs are doubly phosphorylated, ZAP-70 is able to bind. ZAP-70 can then be phosphorylated by LCK at several sites. This phosphorylation has a variety of effects: holding ZAP-70 in an open conformation, increasing ZAP-70 catalytic activity, and allowing ZAP-70 to dissociate from CD3ζ ([@bib22], [@bib38]).

In module II, we modeled the activity of phosphatases known to play a role in T cell activation. This module influences both modules I and III. We included two main phosphatases that act throughout the whole model of T cell activation: CD45 and SHP1. CD45 is constitutively active in T cells and prevents unstimulated T cell activation. SHP1 activity is induced upon phosphorylation of the TCR. To explore its effects on CAR activation, we included a mechanism of negative feedback through phosphatase SHP1 recruitment, first modeled by Altan-Bonnet and Germain ([@bib3]). SHP1 is recruited to singly phosphorylated CD3ζ ITAMs (from module I), where it can be activated by LCK. SHP1 can then dephosphorylate various proteins in the signaling cascades in modules I and III.

Module III, the LAT signalosome, links the output of module I (activated ZAP-70) to the inputs of module IV (active SOS and PLCγ). Module III begins with free and activated ZAP-70 from module I, which is able to phosphorylate LAT. Phosphorylated LAT can bind to adaptor molecules, GADS and Grb2, which in turn bind to other downstream signaling proteins, such as SLP76, and the inputs to module IV, SOS and PLCγ. Phosphorylated CD28 can also bind and recruit several of the proteins in the LAT signalosome.

Module IV focuses on MAPK pathway activation. To initiate this pathway, we adapted a model of Ras-GDP to Ras-GTP conversion by SOS and RasGRP from Das et al. ([@bib12]). Their model details the allosteric regulation of SOS by active Ras, which results in a positive feedback loop that can transform the analog phosphorylation events derived from TCR or CAR activation to a digital ERK response. The RAS-GTP output of this model was used as the input to an MAPK cascade parameterized by Birtwistle et al. ([@bib6]), resulting in doubly phosphorylated ERK. Active ERK also feeds back to modules I and II as it can phosphorylate LCK at a protection site, which prevents interactions with the phosphatase SHP1, as first modeled by Altan-Bonnet and Germain ([@bib3]).

Together, these modules constitute a mechanistic description of what are thought to be the most important interactions in the binary decision of T cells to activate ERK. Below, we explore the model in detail and make predictions about the mechanisms through which the individual signaling domains on CARs influence the ERK response.

Model Parameterization to Literature Data {#sec2.2}
-----------------------------------------

We first fit the model parameters to experimental data to obtain a robust mathematical framework to predict T cell activation leading to ERK phosphorylation ([Figure 2](#fig2){ref-type="fig"}). We started by refitting our previous model of LCK regulation to reduce the computational complexity and better constrain the parameters, as described in the [Methods](#sec4){ref-type="sec"} section. We fit this minimal model of LCK autoregulation and phosphorylation by CSK to five different experimental conditions in the literature ([@bib21]). In total, the values of 11 parameters were estimated using 132 experimental data points.Figure 2Model Parameters Were Fit to Experimental Data(A) A reduced version of our model of LCK regulation ([@bib30]) was refit to data (dots) from Hui and Vale ([@bib21]) for five different experimental conditions using Michaelis-Menten kinetics for all LCK-LCK catalytic interactions and mass action kinetics for all CSK-LCK interactions and LCK-LCK binding interactions. The median value from 100 fitted parameter sets (solid lines) is shown, with the shaded region indicating the standard deviation of the fits.(B) The median value and standard deviation (error bars) of the fitted LCK and CSK parameter values from 100 optimized sets (on log scale). LCK catalytic parameters are denoted as cat_XX\_\#, where XX indicates the phosphorylation state of Y394 and Y505 on the substrate LCK and \# indicates the tyrosine site substrate being phosphorylated. Catalytic parameters for CSK phosphorylation of LCK Y505 are denoted as cat_CSK_XX, where XX indicates the phosphorylation state of the LCK substrate. Dissociation rates are denoted as off_XX_YY, where XX and YY indicate the phosphorylation state of the LCK binding partners at Y394 and Y505, respectively, or CSKoff_XX, where the binding partners are CSK and LCK phosphorylated at Y394 or Y505 as indicated by XX, respectively. All fitted parameters are in units of min^−1^.(C) (*Top row*) CD45 catalytic rate parameters were fit to data from Hui et al. in the absence of CSK ([@bib20]) (dots). The median value of 100 optimized parameter sets (solid lines) is shown, with the shaded region indicating the standard deviation. (*Bottom row*) As validation, the model was simulated with 145 molecules/μm^2^ CSK and compared with data from Hui et al. not used in parameter fitting (open circles; error bars, standard deviation from three independent experiments performed by Hui et al.). The median (lines) and standard deviation (shaded region) of the 100 optimized parameter sets is shown.(D) The median value and standard deviation (error bars) of the CD45 catalytic parameter values from 100 optimized sets (shown on a log scale). CD45 catalytic rates are denoted as Kcat_CD45_x, where x indicates the substrate tyrosine sites. A1 indicates CD3ζ ITAM tyrosine sites. Dephos is a generic dephosphorylation rate applied to all substrates not specifically fit to their own value. Catalytic rates are in units of min^−1^.

[Figure 2](#fig2){ref-type="fig"}A shows the model fit to experimental data. This experimental data was quantified from single replicate Western blot experiments under five experimental conditions for the purpose of comparing the relative phosphorylation rates of the activating (Y394) and inhibitory (Y505) tyrosine phosphorylation sites on LCK ([@bib21]). Therefore, in an effort to ensure that the model is capturing the intended use of the data, the objective function for the model fitting algorithm included a comparison of the relative differences between the phosphorylation of the two sites in addition to the sum of squared error (SSE) between the individual data points and corresponding model simulations. In this way, we ensure that the model is able to capture the relative phosphorylation of the two sites while allowing for the potential of biological and experimental variability, which was not quantified in the single replicate extracted from the paper by Hui and Vale. Therefore, although there are some discrepancies between the model simulations and the single replicate quantitative Western blot data, the model can capture the differences between stimulating and inhibitory site phosphorylation and provide an appropriate prediction for the overall catalytic activity of LCK. In addition, the values of the estimated parameters are within a relatively tight range, indicating that the parameters are identifiable and their values are reliable. The median parameter values as well as the standard deviation for 100 best fit parameter sets are shown in [Figure 2](#fig2){ref-type="fig"}B and are listed in [Table S1](#mmc2){ref-type="supplementary-material"} and the species\' initial concentrations are given in [Table S2](#mmc1){ref-type="supplementary-material"}. The final model is in the [Data S1](#mmc3){ref-type="supplementary-material"}.

The majority of the downstream model parameters come directly from measurements in the literature or from previously published models. However, some of the parameters were not well defined, because they had not been measured experimentally, they had conflicting values after being fit to the specific assumptions of previous models, or they did not account for the two-dimensional nature of the interactions specifically modeled here. This was particularly true of the parameters governing phosphatase activity, which were shown to significantly influence ERK response time in our sensitivity analysis ([Figure 3](#fig3){ref-type="fig"}). To better constrain these parameters, we fit the model to published measurements obtained using an *in vitro* system of recombinant proteins interacting on a two-dimensional liposomal membrane ([@bib20]). Hui et al. used this system, combining twelve proteins involved in T cell activation, to measure nine different protein phosphorylation states in the presence of varying amounts of CD45. We extracted this data (64 data points) and fit seven model parameters, as described in the [Methods](#sec4){ref-type="sec"} section. [Figure 2](#fig2){ref-type="fig"}C, top row, shows the model fit to the experimental data collected in the absence of CSK; best fit parameter values and standard deviations are listed in the [Table S2](#mmc1){ref-type="supplementary-material"}. To validate this parameterized model, we extracted an additional dataset from Hui et al., which includes 145 molecules/μm^2^ CSK (64 data points). As the activity of CSK was fit in our minimal LCK phosphorylation model and was not accounted for in the fitting of the Hui et al. CD45 dephosphorylation data, this validation provides confidence that combining our minimal LCK phosphorylation model with the larger CD45 dephosphorylation model can accurately reproduce the signaling network ([Figure 2](#fig2){ref-type="fig"}C, bottom row). The median parameter values as well as the standard deviation for 100 best fit parameter sets are shown in [Figure 2](#fig2){ref-type="fig"}D and are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.Figure 3First-Order (*S*~*i*~) and Total (*S*~*Ti*~) Sensitivity Indexes of Model Parameters(A) An eFAST sensitivity analysis was performed on all model initial concentrations for two different nominal ranges of antigen (Ant_T), as indicated on the left. Only the initial conditions whose sensitivity indices are statistically significantly different from that of a dummy variable are shown. The relative sensitivities of species in the model change depending on the amount of antigen in the system.(B) Model parameters were separated into nine groups, listed on the left. An eFAST sensitivity analysis was performed on each group with the initial antigen concentration of 100 molecules/μm^2^. Only the parameters whose sensitivity indices are statistically significantly different than that of a dummy variable are shown. For binding interactions with literature-defined K~D~ values, only the k~on~ parameter was chosen to vary in the sensitivity analysis.

Overall, the fitted models of LCK autoregulation and phosphatase interactions qualitatively and quantitatively match the experimental data. Additionally, nearly all of the estimated parameter values lie in a tight range. Altogether, we demonstrate that these models recapitulate experiments and can be combined with the other model components to create a predictive framework of CAR-mediated ERK activation. The median values of the estimated parameters were used in model simulations presented below.

Sensitivity Analysis Reveals Network Features that Control ERK Activation {#sec2.3}
-------------------------------------------------------------------------

To better understand how the model parameters interact with one another and influence the output of doubly phosphorylated ERK response time, we conducted a sensitivity analysis using the extended Fourier amplitude sensitivity analysis (eFAST) method ([@bib24]). This global sensitivity analysis allows us to identify the parameters that the model output is sensitive to both individually, with the first-order sensitivity index (*S*~*i*~), which is analogous to a local sensitivity, and in combination, with the total sensitivity index (*S*~*Ti*~). This analysis is particularly important for large models, similar to the one presented here, which incorporate many different mechanisms of feedback and other complex interactions, as it allows one to look at the effect of individual parameters, as well as the effect of changing multiple parameters together. Parameters with high first-order sensitivity indices strongly influence the model output, and parameters with high total-order sensitivity indices influence the model in combination with other parameters. We note that this analysis is not a global structural analysis and can still change based on model settings, including the stimulation level and the range over which the parameters are allowed to vary. However, it is a powerful way to analyze the importance of the model parameters.

We analyzed the model parameters in seven groups: initial concentrations, CAR parameters, LCK parameters, LAT parameters, RAS parameters, MAPK parameters, and phosphatase parameters. We only list the parameters for which sensitivity indices are statistically significant. Overall, we find that there is at least one parameter in each group that significantly influences ERK response time. Additionally, almost all of the influential parameters have a higher total sensitivity index than first-order index. This indicates that, even if all the parameters in a group are not significantly influential on their own, they do all still interact together to affect the output. We next examine the results of the sensitivity analysis in greater detail.

[Figure 3](#fig3){ref-type="fig"}A shows the sensitivity of the model to the species\' initial concentrations for two different conditions, one with a high range of antigen (100--10,000 molecules/μm^2^, top) and one with a moderate range of antigen (10--1,000 molecules/μm^2^, bottom). The relative sensitivity indices of the initial species concentrations change between these two experimental conditions. This is particularly interesting when considering the impact of the antigen concentration itself and the concentration of the negative feedback molecule, SHP1. At low antigen concentrations, ERK activation is proportional to the amount of antigen in the system. In this regime LCK, ZAP-70 and CSK emerge as highly influential. This is not surprising, as activation of ZAP-70 is an early bottleneck that must occur before the downstream signaling pathways diverge into more complex branched structures through the many elements of the LAT signalosome. The branches of the LAT signalosome activation converge back onto the MAPK pathway; thus, they are able to help compensate for each other and are less influential overall than the upstream decision makers.

At high antigen concentrations, the sensitivity indices of the antigen concentration are greatly reduced, and the strong influence of SHP1 emerges. We sought to further understand the role of SHP1 and antigen concentration in the model, as the eFAST sensitivity analysis indicated that the interaction between these two species was important. In our model, we assume that the intracellular signaling events downstream of CD3ζ activation are the same for the TCR and CARs. As such, our CAR signaling model incorporates a similar form of SHP1 negative feedback that has been shown to play an important role in TCR signaling. This response has been modeled in TCR signaling previously ([@bib3]). We explored this feedback in the model by recording ERK response time for various levels of antigen and SHP1 expression ([Figure S2](#mmc1){ref-type="supplementary-material"}). As antigen concentration increases for high SHP1 concentrations, as well as in intermediate SHP1 levels (above the red line), the ERK response time first decreases and then increases. When SHP1 concentration is low, this longer ERK response for high CD3ζ is not seen, indicating that it is the feedback of SHP1 that is responsible for this shift in the ERK response time trend. These results reveal that, past a certain threshold antigen concentration, the amount of antigen is not significantly important for controlling the rate of T cell activation. Instead, T cell activation is controlled by the intracellular signaling and negative feedback through SHP1.

[Figure 3](#fig3){ref-type="fig"}B shows the sensitivity analysis of the other six groups of parameters starting with a moderate concentration of antigen (100 molecules/μm^2^). The sensitivity indices of these parameters follow similar trends as with the impact of the initial concentrations. Some of the most influential parameters in the model are the catalytic rates of LCK, ZAP-70, PLCγ, RasGRP, and CD45. Additionally, the value of the Michaelis constant (*km*) value is a highly influential parameter, because this single parameter plays a role in every Michaelis-Menten reaction in the system. However, there are not enough data to be able to identify both a catalytic rate and Michaelis-Menten constant for all of these reactions, thus leading to our choice to focus our fitting around the highly sensitive catalytic parameters. The calculated sensitivity indices for the network stimulated with a high concentration of antigen (1,000 molecules/μm^2^) shows similar changes as the initial condition sensitivities, with SHP1 parameters being more sensitive than the low antigen case and ZAP70 and CSK parameters being slightly less sensitive.

Taken together, the high-sensitivity indices of multiple parameters spread throughout the different groups highlights the interconnected nature of the signaling network modeled here, where the final output depends on each step of the pathway to produce a response. Thus, there is not a single category of parameters that solely affects ERK activation. Rather, control of ERK response is distributed across the network.

Model Is Validated by Independent Experimental Datasets {#sec2.4}
-------------------------------------------------------

We next sought to validate the model predictions using experimental data of ERK activation in CAR T cells. In our modeling approach, we assume that the same signaling events that occur downstream of the TCR also occur downstream of the CARs. This assumption has been shown to be true on a macroscale of general phosphorylation events ([@bib15]) but we wanted to further validate it specifically for the negative feedback of SHP1. To do so, we compared model simulations with experimental measurements. First, CAR T cells were made as described in the [Methods](#sec4){ref-type="sec"} section. We used lentiviral vectors to create stable Jurkat T cell lines expressing HA-tagged anti-CD19 CARs (CD3ζ only and CD28-CD3ζ CARs) and sorted them into CAR positive populations ([Figure S1](#mmc1){ref-type="supplementary-material"}). Using 28z^Med^ Jurkat T cells, we verified that anti-HA antibody is able to bind to the HA-tagged CAR and stimulate ERK phosphorylation. Using this system, we stimulated the cells with various amounts of anti-HA antibody, up to very high concentrations, and measured the percent of doubly phosphorylated ERK over time ([Figure 4](#fig4){ref-type="fig"}A). We then fit these responses to a 4-parameter sigmoidal curve, where the lines in [Figure 4](#fig4){ref-type="fig"}A are from simple curve fitting that does not make use of our mechanistic model of CAR signaling. From the fitted sigmoidal curves, we estimated the 95% confidence interval of the half maximal ERK response time at each antibody concentration, referred to as the ERK response time ([Figure 4](#fig4){ref-type="fig"}B, black dots and error bars). For very low concentrations of antibody, the maximal percent of ERK positive cells is very low, making it difficult to fit a sigmoidal curve. Thus, the confidence intervals for the fitted ERK response times are very wide for these low concentrations. However, as we increase the antibody concentration and higher maximal ERK phosphorylation is achieved, the confidence intervals around the fitted ERK response times narrow and we can see a clear trend. As the antibody concentration increases, the ERK response time of the population becomes faster. This trend appears to change at very high antibody concentrations, where the response time begins to slow, presumably, due to the negative feedback from SHP-1, as seen in endogenous T cell signaling ([@bib3]).Figure 4The Model Can Reproduce Effects of T Cell Signaling(A) The percent of ppERK positive 28z^Med^ CAR T cells over time following stimulation with varying amounts of anti-HA antibody. Experimental data (dots) were fit to a sigmoidal curve (lines) to estimate ERK response time (EC50).(B) The model simulations (lines) compared the ERK response time of 28z^Med^ CAR T cell activation (dots), calculated from the ppERK response curves in (A). Experimental data is the sigmoidal fit EC50 value from (A). Error bars, 95% confidence interval. Model simulations using the baseline assumption that SHP1 association rate with singly phosphorylated CD3ζ ITAMs is 0.1 μm^2^molecule^−1^min^−1^ (blue line) do not match the data, but changing the SHP1-ITAM association rate to 0.0015 μm^2^molecule^−1^min^−1^ (red line) allows the model to capture the ERK response data well.(C) The model can qualitatively match the expected changes in ERK response time due to changes to various intracellular signaling molecules. The change in the ERK response compared with the baseline ERK response model is shown for simulations with varying amounts of CSK as well as alterations to the indicated LCK tyrosine sites to mimic a tyrosine to phenylalanine mutation.

We applied the fitted model to predict the ERK response time for the same antigen concentration levels used in our experiments. Given the mechanistic detail of the model, we could use it to investigate whether SHP1 influences CAR signaling in a similar way as in TCR signaling. Using the baseline model parameters, the model simulations qualitatively agree with the experimental observations, showing faster ERK response time with increasing antigen at low concentrations and slowing ERK response time to a plateau at higher concentrations ([Figure 4](#fig4){ref-type="fig"}B, blue line). However, the response times given by the model simulations with the baseline parameters are much slower than the experimental data. To correct this, we examined the assumption that all parameters bind with the same association rate (0.1 μm^2^molecule^−1^min^−1^) made during model construction. Based on experimental evidence, we know that SHP1 must be recruited to the T cell signaling area in lipid rafts in order to exert its inhibitory effects ([@bib23]) and that this recruitment is thought to be mediated by molecules that move to lipid raft membranes ([@bib10]). We accounted for SHP1 recruitment by decreasing the association rate of SHP1 to the singly phosphorylated ITAMs. We tried a range of values for this association rate and found that reducing this rate to 0.0015 μm^2^molecule^−1^min^−1^ allowed the model to match the experimental data. These simulations indicate that SHP1 does indeed play a significant role in CAR signaling. Additionally, we confirm that the model qualitatively and quantitatively matches experimental measurements. We note that simply reducing the concentration of SHP1 does not allow the model to match experimental data. As described earlier, at lower SHP1 concentrations, the model does not predict the longer ERK response for high CD3ζ seen experimentally ([Figure S2](#mmc1){ref-type="supplementary-material"}). We use the reduced SHP1 association rate in all subsequent model simulations.

We next aimed to further validate the model by determining whether it could qualitatively reproduce known experimental observations obtained following modifications of ERK activation, as published in the literature. To do this, we applied the model to test how different mutations to upstream signaling molecules influence downstream ERK response time ([Figure 4](#fig4){ref-type="fig"}C). Schoenborn et al. modified CSK experimentally to produce a form of the protein that can specifically bind to a small molecule inhibitor ([@bib36]). They showed that inhibiting CSK resulted in faster ERK activation in a population of T cells. When we remove CSK from the model, the model predicts that ERK response time increases by almost one minute, in agreement with the findings from Schoenborn and coworkers. Conversely, when we double the amount of CSK, the model shows that ERK response time slows.

In the same study, Schoenborn et al. also showed that CD45-deficient cells have reduced ERK activation upon TCR stimulation. Using the model, we show that removing CD45 greatly slows the ERK response time by roughly 2.75 min. These model simulations qualitatively agree with the experimental data.

Similar experiments were done by Philipsen et al. to test the ERK response, given various LCK tyrosine to phenylalanine mutants expressed in LCK-negative Jurkat T cells ([@bib29]). They found that LCK-Y394F or LCK-Y394F-Y505F essentially eliminated the ERK-positive cell population at 3 min, whereas LCK-Y505F increased the amount of ERK-positive cells. Implementing these two mutations in our model shows that removing LCK-Y394 phosphorylation completely prevents LCK phosphorylation, whereas removing LCK-Y505 phosphorylation speeds up the ERK response time. Because our model does not incorporate stochasticity, we cannot directly measure the percentage of positive cells. However, these trends agree with the experimental findings. Thus, the model is able to capture known effects of signaling modifications in both TCR- and CAR-specific T cell activation.

Model Analysis Predicts Mechanism of CD28-Enhanced Signaling {#sec2.5}
------------------------------------------------------------

The results presented above show the development and validation of a predictive model of ERK activation in CAR28z T cells. However, in our eFAST sensitivity analysis, none of the CD28 signaling parameters emerged as statistically significantly sensitive with respect to ERK response time. This was unexpected, as ERK phosphorylation has been shown to be a key step in T cell activation and proliferation ([@bib3]), and CD28 is known to play a significant co-stimulatory role affecting the degree of these responses. To further explore this result from the sensitivity analysis and better understand how various observed mechanisms of CD28 signaling influence ERK activation, a long-standing question in the field of immunology ([@bib2], [@bib5]), we systematically explored the different mechanisms of CD28 represented in the model.

Specifically, we systematically altered the model to include three mechanisms related to CD28 signaling, which have been described previously in the literature and are shown in [Figure 5](#fig5){ref-type="fig"}. The first two involve proteins that interact with CD28 directly via phosphorylated tyrosine sites and proline-rich regions, enabling binding of the adaptor proteins Grb2 and GADS ([@bib17]). (1) Grb2 is able to recruit SOS to the signaling area, which can activate Ras and the MAPK pathway directly ([Figure 5](#fig5){ref-type="fig"}A) ([@bib35]). (2) GADS is able to recruit SLP76, thus increasing the amount of this adaptor protein in the signaling region ([Figure 5](#fig5){ref-type="fig"}B) ([@bib37], [@bib40]). For Grb2 and GADS binding, we assume that these adaptor proteins will bind and signal in the same way that they do on the LAT signalosome. (3) The third mechanism uses the kinetic rates calculated in our previous model of phosphorylation of the individual CD3ζ ITAM sites in the presence of CD28. In this mechanism, the increased phosphorylation rate of CD3ζ allows for faster recruitment of ZAP-70 and therefore faster activation of the LAT signalosome and the MAPK pathway ([Figure 5](#fig5){ref-type="fig"}C) ([@bib32]).Figure 5Systematic Analysis of CD28 Mechanism Contribution to ERK Activation(A) (*Top*) CD28 can bind to Grb2, which can bind to SOS and activate the MAPK pathway and ERK. (*Bottom*) ERK response time as a function of CD3ζ concentration for the Z (blue) or 28z (red) CAR in which the only effect of CD28 activation is its binding to Grb2.(B) (*Top*) CD28 can bind to GADS, which can potentially bind to SLP76. Tec family kinases recruited by SLP76 can then activate PLCγ on the LAT signalosome, which activates MAPK pathway and ERK. (*Bottom*) ERK response time as a function of CD3ζ concentration for the Z (blue) or 28z (red) CAR in which the only effect of CD28 activation is its binding to GADS.(C) (*Top*) The presence of CD28 on the N-terminal of CD3ζ has been shown to increase the rate of CD3ζ phosphorylation by LCK. This leads to faster assembly of the LAT signalosome and activation of the MAPK pathway and ERK. (*Bottom*) ERK response time as a function of CD3ζ concentration for the Z (blue) or 28z (red) CAR in which the only effect of CD28 activation is to increase the rate of phosphorylation of CD3ζ.

To understand the relative importance of each of these three mechanisms (Grb2 binding to CD28, GADS binding to CD28, and CD28-mediated enhancement of LCK activity) on ERK activation in CAR T cells, we performed a systematic analysis of CD28 in the model by implementing each of these mechanisms alone and in combination to understand their effect on ERK activation. We note that we do not fit or further tune any model parameters. Rather, we directly implement the proposed mechanisms by either setting the binding association rates of CD28 with Grb2 or GADS (*CD28_Grb2_on* and *CD28_GADS_on*, respectively) to zero or setting the LCK phosphorylation parameters for CD3ζ to the values for LCK phosphorylation of CD3ζ without CD28, calculated in our previous work ([@bib32]) ([Table S2](#mmc1){ref-type="supplementary-material"}). We present simulation results obtained using the median value of the 100 optimal parameter sets from PSO, as the optimal parameters show consistent results. The bottom panels of [Figure 5](#fig5){ref-type="fig"} show the predicted ERK response time as a function of antigen concentration for each individual mechanism of CD28 activation compared with the simulated case where the CAR only expresses the CD3ζ domain. Both Grb2 and GADS binding showed similar effects: slightly slowing ERK response time at low antigen concentrations, with only minor effects at high antigen concentrations. In contrast, the effect of the increased rate of CD3ζ phosphorylation was significantly different, showing a nearly constant decrease in response time in the presence of CD28 over all antigen concentrations. Simulating Grb2 and GADS binding together did not appear qualitatively different than simulations with each one individually ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Adding either or both binding mechanisms to the mechanism of increased LCK kinetics was not significantly different from the increased kinetics mechanism alone ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3D).

In summary, our model simulations indicate that the way in which CD3ζ phosphorylation is increased in the CAR due to the presence of CD28 speeds up the ERK response time across the full range of stimulation levels simulated. In comparison, the effects of adaptor proteins binding to CD28 only shorten the ERK response time at high stimulation levels. This is in agreement with the eFAST sensitivity results, which showed that ERK response time is not significantly sensitive to parameters relating to CD28 binding to adaptor proteins, but it is sensitive to the rate of CD3ζ phosphorylation by LCK. Thus, the model predicts that dynamics produced by adaptor proteins binding to CD28 are significantly different than those produced by implementing increased CD3ζ phosphorylation.

To test these model predictions, we quantified how the presence of CD28 affects downstream signaling leading to ERK activation by measuring the ERK response time for Z or 28z CAR T cells. To do this, we used the Z and 28z CAR-expressing Jurkat T cells, following the same protocol and sorting process described earlier. We also expressed CD19 on K562 target cells and sorted them into different expression levels as described in the [Methods](#sec4){ref-type="sec"} ([Figure S1](#mmc1){ref-type="supplementary-material"}B). We then stimulated 28z^Med^ and Z^Med^ T cells with different ratios of 19^Med^ target cells and measured the ERK response time ([Figures 6](#fig6){ref-type="fig"}A and 6B). In this way, we mimic cell-cell interactions mediated by CAR-CD19 binding, rather than using anti-HA antibodies (as was done for model validation, shown in [Figures 4](#fig4){ref-type="fig"}A and 4B) or a CD19 antibody. Here, we see that the 28z CAR has consistently faster ERK activation for all target cell ratios. We further verified the results by stimulating 1:1 ratios of high-, medium-, and low-expression CAR and target cells and measuring the ERK response time ([Figure S1](#mmc1){ref-type="supplementary-material"}C). The ERK response time depends on both CAR expression level and CD19 expression level, with high expressing cells displaying faster response times than lower expressing cells. Additionally, 28z CARs had consistently faster ERK response times compared with Z CARs.Figure 6Experimental Validation of CAR Activated ERK Response Time(A) Z^Med^CAR cells and 28z^Med^ CAR cells were mixed with various amounts of 19^Med^ K562 cells, and the ERK response was measured over time. The data (dots) were then fit to a sigmoidal curve (lines), and the ERK response time (EC50) was calculated.(B) Experimental ERK response time of Z^Med^ and 28z^Med^ CAR T cell activation (dots). Experimental data are the EC50 value from the sigmoidal curves fit in (a). Error bars, 95% confidence interval.

Comparing these results with the model simulations in [Figure 5](#fig5){ref-type="fig"}, we can see that the model in which CD28 influences the kinetics of LCK phosphorylation of CD3ζ qualitatively matches the experimental data. The difference in the absolute quantification of ERK response times between the target-cell-stimulated data and the model is likely due to the fact that the model was fit to experimental data of CAR stimulation through anti-HA antibodies, which may be less efficient at inducing strong cross-linking between signaling receptors and bind more diffusely over the T cell surface compared with the clustering of proteins that can occur within the cell-cell binding interface. However, the model closely predicts the qualitative effects of CAR stimulation.

Therefore, based on these model simulations and comparison to experimental data, we hypothesize that CD28 primarily influences ERK activation through recruitment of LCK, which increases the kinetics of CD3ζ activation, and not through specific binding events of the CD28 protein itself.

Model Predicts Effects of Removing CD3ζ ITAMs {#sec2.6}
---------------------------------------------

The results presented above demonstrate how we have developed a mathematical model to predict ERK activation downstream of CAR signaling. By comparing the simulations to multiple independent datasets, we present a validated model that can generate reliable, experimentally based results. This provides confidence that the model can be used to generate new predictions and testable hypotheses.

We present one such set of hypotheses in [Figure 7](#fig7){ref-type="fig"}. Specifically, we applied the model to predict the effects of various inactivating mutations of ITAM tyrosine sites on CD3ζ CARs with or without CD28. The model predicts that reducing the number of ITAMs on the CD3ζ domain can increase the ERK response rate of both CARz and CAR28z T cells. At low antigen concentrations, this effect is more pronounced for CARz than CAR28z, but at high antigen concentrations, this effect is clearly evident for both types of CARs. The largest reduction in ERK response time is seen for mutations of the first two ITAMs on CD3ζ, with a 1.7-min reduction for CARz ERK response time and a 1.3-min reduction for CAR 28ζ ERK response time at antigen concentrations of 3 μM ([Figure 7](#fig7){ref-type="fig"}D). The model predicts that removing ITAM sites reduces the amount of singly phosphorylated ITAMs that recruit the SHP1-negative feedback. Thus, the most pronounced effects occur at high antigen concentrations where that negative feedback is strongest. The model predictions agree with experiments showing that CAR T cells with single ITAMs can have more optimal activation properties ([@bib14]) (reviewed in detail in [@bib9]). Thus, the model could be used in the future to make CAR structures that are optimally activated at a specific antigen concentration, which could help the design of CARs with less on-target off-tumor toxicity.Figure 7Model Predictions of CD3ζ ITAM MutantsModel predicted ERK response time for WT CARz or CAR28 compared with CARs with Y to F mutations of the two tyrosine sites on (A) ITAM A, (B) ITAM B, (C) ITAM C, (D) ITAM A and ITAM B, (E) ITAM A and ITAM C, and (F) ITAM B and ITAM C.

Discussion {#sec3}
==========

In this study, we developed a computational mechanistic model of the signaling events that lead to activation of CAR-engineered T cells via MAPK signaling. To our knowledge, this is the first model to combine this level of detail of the T cell activation signaling and co-stimulatory pathways. The model incorporates 23 different proteins in the signaling pathway that leads from CAR-antigen binding to ERK activation. Experiments quantifying ERK activation in CAR-bearing Jurkat T cells were used for model parameterization and validation. The validated model was used to explore CAR signaling and how the CD28 co-stimulatory domain influences ERK activation. We performed a systematic analysis by implementing three distinct CD28 signaling mechanisms supported by published literature to explore the way in whichdifferent CD28 signaling mechanisms influence ERK activation kinetics. We show that CD28 primarily affects downstream signaling through recruiting LCK to modify the phosphorylation rate of CD3ζ and that the binding properties of CD28 alone may actually retard T cell activation at low antigen concentrations. In addition, we confirmed the importance of SHP1-negative feedback in CAR signaling and made new predictions about how antigen concentration and ITAM number influences CAR T cell activation.

The model was first parameterized based on estimated values from experimental measurements and previous models in the literature ([@bib3], [@bib6], [@bib12], [@bib17], [@bib19], [@bib30]). We then performed a global sensitivity analysis to determine which parameters most strongly influence the ERK response time. From this analysis, we found that the upstream parameters controlling catalytic rates of LCK, ZAP-70, and the phosphatase CD45 were particularly important in influencing the ERK response time. These parameters were not well defined in the literature; however, we highlight their importance in this signaling pathway. We believe this provides more motivation to better determine the values of those parameters experimentally in the future.

Once the model was fully parameterized, we ensured that it could reproduce experimental CAR-specific T cell activation data as well as observations for TCR-stimulated T cell ERK in the literature. Tuning the SHP1 association rate with singly phosphorylated ITAMs allowed for our model to fit ERK activation data for anti-HA antibody-stimulated 28z CAR T cells. The model was also able to capture the effects of various signaling modifications on T cell ERK activation, indicating that the model is robust.

Given the mechanistic detail of the model, we could perform simulations to distinguish the possible ways that the CD28 co-stimulatory domain affects ERK response time in engineered T cells. CD28 is known to bind to several different adaptor proteins that can recruit activators of Ras and the MAPK pathway ([@bib17], [@bib39]). We also included a finding from our previous work that CD28 increases the phosphorylation rate of CD3ζ ([@bib32]), which in turn could lead to more rapid LAT signalosome formation and ERK activation ([@bib18]). We explored each of these mechanisms alone and in various combinations to develop model-driven hypotheses about how each one would affect the ERK response time. We compared these predictions with experimental data of ERK response time differences between Z and 28z CAR T cells stimulated with a 1:1 ratio of CD19-expressing target cells. These experiments qualitatively match the model predictions that the main role of CD28 is to increase CD3ζ phosphorylation kinetics. We note that we assessed how the three signaling mechanisms (Grb2 binding, GADS binding, or enhanced LCK catalytic activity) are compared with experimental data using the baseline fitted parameters from model construction without additional fitting. We believe that the significance of the model assessment is that we can demonstrate the differences between the CD3ζ and CD3ζ-CD28 CARs observed experimentally without additional hand tuning.

The insights from the model increase our understanding of how CD28 is functioning in T cells. It also generates new hypotheses that can be tested experimentally. Specifically, in the model, the mechanism through which CD28 is able to increase CD3ζ phosphorylation kinetics is not clear. One possibility is that the CD28 domain alters the structure of the CAR on the inner membrane of the T cell to make it more accessible to rapid phosphorylation. Alternatively, CD28 has binding sites for LCK that could be increasing the local concentration of this CD3ζ activating kinase, thus allowing for more rapid phosphorylation. It would be interesting to further test these hypotheses experimentally to more specifically isolate the structural features of CD28 that improve CAR activation. The model also predicts that CD28 binding to GADS and Grb2 may retard T cell ERK activation at low antigen levels. More experimental work is needed to understand the extent of this retardation and how it can be harnessed or modified to improve CAR T cell activation. This iterative approach between hypothesis generation and experimental testing can be used to make more optimal next generation CARs.

We also demonstrate that removing one or two ITAMs from CD3ζ can speed up ERK response time and reduce negative feedback that slows response at high antigen concentrations and leads to an optimal antigen concentration for T cell response. Similar effects have been shown experimentally in the literature and could be particularly important for CARs because they have typically been used to target tumor-specific antigens that are overexpressed on tumors ([@bib14]). However, the model provides additional insights into how the antigen concentration influences the T cell response for different CAR ITAM mutants. The model shows that reducing the number of ITAMs leads the ERK response time to approach an asymptote as antigen concentration increases. These insights could be used in the future to better design CARs that take advantage of the optimal response time seen with higher numbers of ITAMs to reduce on-target off-tumor toxicities. More work still needs to be done to link these short-term activation signals to long-term T cell phenotypic responses; however, modeling can help provide a basis to verify our understanding of the system and guide future experiments in a more rational way.

Altogether, the mechanistic model of CAR-mediated T cell signaling we have constructed is able to reproduce known effects of CAR activation of the ERK/MAPK pathway and shed new light on the mechanisms of CAR co-stimulatory signaling through CD28. The model indicates a dominant mechanism for the modification of ERK response time by CD28, which matches experimental data. Additionally, the model provides new hypotheses that can be tested experimentally to better understand how to modulate the effects of CD28 signaling in CAR therapies. Thus, the model provides a framework that can be used to better understand and optimize CAR-engineered T cell development.

Limitations of the Study {#sec3.1}
------------------------

We do acknowledge some limitations of our study, including the model itself, model fitting and comparison to experimental data, and the data used for model construction and validation.

We made some assumptions related to the structure of the current model. First, there are additional mechanisms in the literature through which CD28 could influence ERK signaling, such as through blocking small G protein Rap1 ([@bib8]). Although we cannot rule out the importance of these alternative signaling mechanisms in our current work, we do believe that the results indicate a strong dependence on the CD28 mechanism of increased LCK recruitment. This mechanism is able to fully match the difference in ERK response times between Z and 28Z CAR T cells, as well as dominate the inhibitory effects of competitive recruitment of other adaptor proteins, as seen in both the GADS and Grb2 mechanisms at low antigen concentrations. Thus, we might expect a similar dominance of the CD28-LCK mechanism over other possible signaling mechanisms. Additionally, the model does not indicate how CD28 influences other downstream T cell activation pathways. In the literature, CD28 has been shown to bind to PI3K, which activates the Akt pathway ([@bib1], [@bib33]). Additionally, CD28 co-stimulation with the TCR can increase the amount of active Vav in the T cell ([@bib16], [@bib28]). These mechanisms are not specifically included in the model, but it is possible that these pathways may crosstalk with the MAPK pathway and further influence ERK activation ([@bib11], [@bib13]). This work does not explore the differences between CD28 signaling when incorporated on the CAR compared with signaling through the traditional separate CD28 molecule, which could have additional implications for dual-target CAR therapies ([@bib25]). As new data emerge, the model can be updated to include these alternative mechanisms to help improve our understanding of how CD28 co-stimulatory signaling can be optimized in CAR T cells.

We do not perform additional fitting when comparing the three models that account for the possible ways in which CD28 enhances ERK response time. An alternative approach is to explicitly fit each model to the experimental data for the ERK response time by optimizing the model parameters. However, by fitting many more parameters, we would encounter a common issue in model optimization wherein the estimated parameter values are not well constrained, given the number of fitted parameters compared with the data available for fitting. In addition, to quantify the goodness of fit such as the sum of the squared errors, we need a quantitative estimate of the antigen concentration used in the experiments (that is, the CD19 density on the surface of the K562 cells used), rather than a qualitative sorting of the cells with high, medium, and low CD19 expressions ([Figure S1](#mmc1){ref-type="supplementary-material"}B, right panel). For these reasons, a qualitative comparison with the experimentally measured ERK response time is most appropriate.

Finally, we acknowledge limitations regarding the data. We have relied on experimental measurements obtained using the Jurkat T cell line, rather than primary T cells. In particular, it has been shown that TCR-proximal signaling in this cell line does not match observations made using primary cells ([@bib4]). Our model provides a robust framework to make novel predictions regarding CAR-mediated signaling that can be confirmed using primary T cells.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

Model code is provided as an SBML model file (Data S1.xml).

Supplemental Information {#appsec3}
========================

Document S1. Transparent Methods, Figures S1--S3, and Table S2Table S1. Model Parameter Values, Related to Figure 1Data S1. SBML Model, Related to Figure 1
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